$PFE

Right now, this is a company with high yield but relatively slow dividend growth

A current EPS of 2.74 could be worrisome as well depending on the quality of that rating

However, profit margins are very high compared to other pharmaceutical competitors https://t.co/lsmEZg9TlJ